


Listing of the claims

This listing of claims provided below will replace all prior versions.

1. (cancelled)
2. (currently amended) A method of inhibiting the binding of a p56^{lck} molecule via an SH2 domain thereof to a corresponding cellular binding protein, or inhibiting the activity of a p56^{lck} molecule via an SH2 domain thereof, comprising administering to a patient in need thereof a compound of formula I or a pharmaceutically acceptable salt thereof



wherein,

B is a phenyl ring,

D is a phenyl ring,

A is, in each case independently of each other, a 5-membered saturated or partially or fully unsaturated heterocyclic ring containing 1 or 2 heteroatoms selected from O, S, and N;



Q is a bond or an alkylene or alkenylene group containing 1-5 carbon atoms, which is optionally substituted with =O, and in which optionally a carbon atom is replaced with an N atom;

Z₁ is, in each case independently, =O, =NH, or alkyl containing 1 to 5 carbon atoms,


Z₂ is, in each case independently, halogen, alkyl containing 1-5 carbon atoms, or CO₂H,

Z₃ is, in each case independently, alkyl containing 1-5 carbon atoms, and

n is, in each case independently, 0, 1, 2, or 3, wherein the compounds or a pharmaceutically acceptable salt thereof that is administered is selected from the group consisting of:



and



3. (cancelled)
4. (withdrawn/currently amended) A method of claim 2 ~~claim 1~~, wherein immunosuppression is affected.
5. (withdrawn/currently amended) A method of claim 2 ~~claim 1~~, wherein said patient suffers from an autoimmune disease or from transplant rejection.
6. (withdrawn) A method of claim 5, wherein said patient suffers from rheumatoid arthritis.
7. (currently amended) A method of claim 2 ~~claim 1~~, wherein said patient suffers from a

neoplasm or a hyperplasia.

8. (original) A method of claim 7, wherein said patient suffers from a benign or malignant tumor.

9. (withdrawn/currently amended) A method of claim 2 ~~claim 1~~, wherein said patient suffers from a depressed immune system.

10. (currently amended) A method of claim 2 ~~claim 1~~, wherein said patient suffers from leukemia, lymphoma, ovarian cancer or breast cancer.

11. (currently amended) A method of claim 2 ~~claim 1~~, wherein said patient is human.

12-14. (cancelled)

15. (withdrawn/currently amended) A method of claim 2 ~~claim 12~~, wherein the compound of number 73 ~~or 92~~ or a pharmaceutically acceptable salt thereof is administered.


16-18. (cancelled)

19. (currently amended) A method of claim 2, wherein the compound ~~of formula I~~ has a solubility such that the ClogP value is ≤ 5 , a molecular weight of ≤ 500 Daltons, and ≤ 10 hydrogen bond donors and acceptors.


20-22. (cancelled)

23. (withdrawn) A pharmaceutical composition according to claim 3 comprising a compound of formula I to IX or a pharmaceutically acceptable salt thereof.

24. (currently amended) A method of claim 2 ~~claim 1~~, wherein the compound is



25. (currently amended) A method of claim 2, ~~claim 1~~ wherein the compound is



26. (new) A method of claim 2, wherein the compound is

